Flow chart of inclusion and exclusion criteria. حسب Ho Geol Woo (7180775)

"…Contrary to AD, treatment of VV group was significantly associated with decreased risk of VD (HR: 0.566, 95% CI: 0.382–0.841). …"

Baseline characteristics of study participants. حسب Ho Geol Woo (7180775)

"…Contrary to AD, treatment of VV group was significantly associated with decreased risk of VD (HR: 0.566, 95% CI: 0.382–0.841). …"

Dynamic characteristics of (A) FIB and (B) PCT between the survival and deceased groups of SFTS patients with HLH. حسب Bo Zhang (6559)

The basic characteristics of the included studies. حسب Junyin Pan (20700411)

الموضوعات:

Common definitions and criteria for metabolic syndrome. حسب Junyin Pan (20700411)

الموضوعات:

Assessment of study bias in the included research. حسب Junyin Pan (20700411)

الموضوعات:

Summary of subgroup analysis results. حسب Junyin Pan (20700411)

الموضوعات:

Original study data. حسب Junyin Pan (20700411)

الموضوعات:

Results of the effect of dietary anthocyanins on health outcomes, including effect size and heterogeneity analysis. حسب Junyin Pan (20700411)

الموضوعات:

Forest plot. حسب Junyin Pan (20700411)

الموضوعات:

S2 File - حسب Junyin Pan (20700411)

الموضوعات:

Funnel plot. حسب Junyin Pan (20700411)

الموضوعات:

Summary of studies identified in the literature search, including studies excluded from the analysis and reasons for exclusion. حسب Junyin Pan (20700411)

الموضوعات:

The flow chart of study selection process. حسب Junyin Pan (20700411)

الموضوعات:

Data extracted from included studies for the systematic review and meta-analysis. حسب Junyin Pan (20700411)

الموضوعات:

Specifications and outcomes of clinical trial studies included in the meta-analysis. حسب Junyin Pan (20700411)

الموضوعات:

Blood Pressure and LDL-C During Follow-up. حسب Karl Ingard (22582091)

"…During a mean follow-up of 3.8 years, 31.7% (n = 64) of the patients in the intervention group and 37.5% (n = 72) in the control group reached the primary endpoint (HR 0.82, 95% CI 0.58–1.14, <i>P</i> = 0.23). The risk of cardiovascular death was significantly decreased (HR 0.64, 95% CI 0.41–0.998, <i>P</i> = 0.049) and the risk of fracture non-significantly increased (HR 1.47, 95% CI 0.95–2.27, <i>P</i> = 0.08) in the intervention group compared to the control group.…"

Baseline Characteristics of Included Patients. حسب Karl Ingard (22582091)

"…During a mean follow-up of 3.8 years, 31.7% (n = 64) of the patients in the intervention group and 37.5% (n = 72) in the control group reached the primary endpoint (HR 0.82, 95% CI 0.58–1.14, <i>P</i> = 0.23). The risk of cardiovascular death was significantly decreased (HR 0.64, 95% CI 0.41–0.998, <i>P</i> = 0.049) and the risk of fracture non-significantly increased (HR 1.47, 95% CI 0.95–2.27, <i>P</i> = 0.08) in the intervention group compared to the control group.…"

Calibration of standards. حسب Asif Khan (1740271)

"…<i>erecta</i> may be a promising medicinal agent for reducing the risk and progression of Parkinson’s disease.</p></div>…"

Appearance of standards under UV 365 nm. حسب Asif Khan (1740271)

"…<i>erecta</i> may be a promising medicinal agent for reducing the risk and progression of Parkinson’s disease.</p></div>…"